Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: fezolinetant; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Clearwater, Florida • Miami, Florida • Orlando, Florida + 1 more

Conditions: Healthy Volunteers
Interventions: Apremilast Tablet, Apremilast Oral Suspension; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: furosemide 80 mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sudden Cardiac Death
Interventions: Ovatio VR 6250 or DR6550; Device
Lead sponsor: LivaNova; Industry
Eligibility: Not listed
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 7
States / cities: Sheffield, Alabama • Tarzana, California • Atlanta, Georgia + 4 more

Conditions: Inflammatory Bowel Disease, Crohn Disease
Interventions: Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years to 20 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Juvenile; Scoliosis, Scoliosis Idiopathic, Scoliosis; Adolescence, Scoliosis;Congenital, Kyphosis, Spondylolisthesis, Pectus Surgery, Hip Surgery
Interventions: Fast-Dissolve Melatonin Pill, Fast-Dissolve Placebo Pill; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Neoplasms
Interventions: Niraparib Tablet, Niraparib Capsule; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 16
States / cities: Encinitas, California • Fresno, California • Denver, Colorado + 13 more

Conditions: Kidney Diseases
Interventions: Kidney Transplant Fast Track (KTFT), Peer Navigation (PN); Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Healthy
Interventions: Clarithromycin, Biaxin®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 2
States / cities: East Grand Forks, Minnesota • Fargo, North Dakota

Conditions: Healthy Adults
Interventions: Crucera-SGS, Meriva 500-SF; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: BUSPAR® 30 mg Tablet, Buspirone Hydrochloride 30 mg Tablet; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Muscular Atrophy, Spinal
Interventions: risdiplam, omeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Interventions: FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo; Dietary Supplement
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 62 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Uveitis
Interventions: Mycophenolate mofetil, Methotrexate, Prednisone; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Portland, Oregon

Conditions: Renal Impairment
Interventions: BPN14770; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Cardiovascular Disease, Inflammatory Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 37 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pre Diabetes
Interventions: Hyperinsulemic euglycemic clamp, Muscle Biopsy, Oral abscisic acid (ABA), Placebo; Other · Procedure · Dietary Supplement
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Volunteers
Interventions: Glasdegib, Rifampin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension, Eating Behaviors
Interventions: Early time-restricted eating; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Centanafadine; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 9 Years to 12 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Invasive Breast Cancer, Post-mastectomy
Interventions: Radiotherapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 30 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function

Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension

Bioequivalence Study of Furosemide 80mg Tablets Under Fasting Conditions

Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications

Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

Studying Melatonin and Recovery in Teens

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

Access to Kidney Transplantation in Minority Populations

Clarithromycin 500 mg Tablets Under Fasting Conditions

Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin

Buspirone Hydrochloride 30mg Tablets, Non-Fasting

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Non-fasting Conditions

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

Methotrexate and Mycophenolate Mofetil for UVEITIS

Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls

Effect of Fasting on the NLRP3 Inflammasome

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Early Time-Restricted Eating in Older Adults With Hypertension

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer